异甘草酸镁联合强的松治疗自身免疫性肝炎的临床价值分析(1)
【摘要】 目的 研究異甘草酸镁联合强的松治疗自身免疫性肝炎(AIH)的临床应用价值。方法 54例自身免疫性肝炎患者， 随机分A组、B组和C组， 各18例。A组给予强的松治疗， B组给予异甘草酸镁联合强的松治疗， C组给予异甘草酸镁治疗。观察比较三组临床疗效、肝功能各项指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)]改善情况及不良反应发生情况。结果 A组总有效率为88.89%， B组为94.44%， C组为61.11%；A组总有效率与B组比较差异无统计学意义(P>0.05)；B组总有效率高于C组， 差异有统计学意义(P<0.05)。治疗后， A组ALT、AST、TBIL分别为(59.8±6.8)U/L、(57.4±5.0)U/L、(27.6±2.9)μmol/L；B组分别为(59.1±6.4)U/L、(56.3±4.8)U/L、(26.4±2.3)μmol/L；C组分别为(64.5±6.3)U/L、(76.4±5.2)U/L、(40.4±3.7)μmol/L；治疗后， B组肝功能各项指标水平明显低于C组(P<0.05)；A、B两组肝功能各指标水平比较差异无统计学意义(P>0.05)。治疗期间A组出现水肿3例、头昏2例， 消化道出血2例， 不良反应发生率为38.89%；B组出现水肿1例， 不良反应发生率为5.56%；C组出现头昏1例， 不良反应发生率为5.56%；A组不良反应发生率明显高于B组和C组， 差异有统计学意义(P<0.05)。结论 异甘草酸镁联合强的松治疗自身免疫性肝炎临床疗效显著， 不良反应少， 临床可积极推广应用。
【关键词】 自身免疫性肝炎；异甘草酸镁；强的松；临床价值
DOI：10.14163/j.cnki.11-5547/r.2016.33.048
Analysis of clinical value of magnesium isoglycyrrhizinate combined with prednisone in the treatment of autoimmune hepatitis LI Zhi-wei. Guangdong Jiangmen City Wuyi Hospital of Traditional Chinese Medicine/Jiangmen Affiliated Hospital of Jinan University， Jiangmen 529000， China
【Abstract】 Objective To research clinical application value of magnesium isoglycyrrhizinate combined with prednisone in the treatment of autoimmune hepatitis (AIH). Methods A total of 54 patients with autoimmune hepatitis were randomly divided into group A， group B and group C， with 18 cases in each group. Group A received prednisone for treatment， group B received magnesium isoglycyrrhizinate combined with prednisone for treatment， and group C received magnesium isoglycyrrhizinate for treatment. Observation and comparison was made on clinical effects， improvement of liver function indexes [alanine transaminase (ALT)， aspartate aminotransferase (AST) and total bilirubin (TBIL)] and adverse reactions in the three groups. Results Group A had total effective rate as 88.89%， group B as 94.44% and group C as 61.11%. There was no statistically significant difference of total effective rate between group A and group B (P>0.05). Group B had higher total effective rate than group C， and the difference had statistical significance (P<0.05). After treatment， group A had ALT， AST and TBIL respectively as (59.8±6.8) U/L， (57.4±5.0) U/L and (27.6±2.9) μmol/L， group B as (59.1±6.4) U/L， (56.3±4.8) U/L
and (26.4±2.3) μmol/L， and group C as (64.5±6.3)U/L， (76.4±5.2) U/L， and (40.4±3.7) μmol/L. group B had lower lung function indexes after treatment than group C (P<0.05)； there were no statistically significant difference in lung function indexes between group A and group B (P>0.05). During treatment， group A had 3 edema cases， 2 dizziness cases and 2 gastrointestinal bleeding cases， with incidence of adverse reactions as 38.89%. There was 1 edema case in group B， with incidence of adverse reactions as 5.56%. There was 1 dizziness case in group C， with incidence of adverse reactions as 5.56%. Group A had obviously higher incidence of adverse reactions than groups B and C， and the difference had statistical significance (P<0.05). Conclusion Combination of magnesium isoglycyrrhizinate and prednisone shows remarkably clinical effect and few adverse reations in treating autoimmune hepatitis， and it is worth actively clinical promotion and application., 百拇医药(李志伟)
【关键词】 自身免疫性肝炎；异甘草酸镁；强的松；临床价值
DOI：10.14163/j.cnki.11-5547/r.2016.33.048
Analysis of clinical value of magnesium isoglycyrrhizinate combined with prednisone in the treatment of autoimmune hepatitis LI Zhi-wei. Guangdong Jiangmen City Wuyi Hospital of Traditional Chinese Medicine/Jiangmen Affiliated Hospital of Jinan University， Jiangmen 529000， China
【Abstract】 Objective To research clinical application value of magnesium isoglycyrrhizinate combined with prednisone in the treatment of autoimmune hepatitis (AIH). Methods A total of 54 patients with autoimmune hepatitis were randomly divided into group A， group B and group C， with 18 cases in each group. Group A received prednisone for treatment， group B received magnesium isoglycyrrhizinate combined with prednisone for treatment， and group C received magnesium isoglycyrrhizinate for treatment. Observation and comparison was made on clinical effects， improvement of liver function indexes [alanine transaminase (ALT)， aspartate aminotransferase (AST) and total bilirubin (TBIL)] and adverse reactions in the three groups. Results Group A had total effective rate as 88.89%， group B as 94.44% and group C as 61.11%. There was no statistically significant difference of total effective rate between group A and group B (P>0.05). Group B had higher total effective rate than group C， and the difference had statistical significance (P<0.05). After treatment， group A had ALT， AST and TBIL respectively as (59.8±6.8) U/L， (57.4±5.0) U/L and (27.6±2.9) μmol/L， group B as (59.1±6.4) U/L， (56.3±4.8) U/L
and (26.4±2.3) μmol/L， and group C as (64.5±6.3)U/L， (76.4±5.2) U/L， and (40.4±3.7) μmol/L. group B had lower lung function indexes after treatment than group C (P<0.05)； there were no statistically significant difference in lung function indexes between group A and group B (P>0.05). During treatment， group A had 3 edema cases， 2 dizziness cases and 2 gastrointestinal bleeding cases， with incidence of adverse reactions as 38.89%. There was 1 edema case in group B， with incidence of adverse reactions as 5.56%. There was 1 dizziness case in group C， with incidence of adverse reactions as 5.56%. Group A had obviously higher incidence of adverse reactions than groups B and C， and the difference had statistical significance (P<0.05). Conclusion Combination of magnesium isoglycyrrhizinate and prednisone shows remarkably clinical effect and few adverse reations in treating autoimmune hepatitis， and it is worth actively clinical promotion and application., 百拇医药(李志伟)